Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

Merger Mania

May 18, 2009 | A version of this story appeared in Volume 87, Issue 20

MERCK IS PAYING $41 billion for Schering-Plough, which paid AzkoNobel $14 billion for Organon Biosciences, while Pfizer is set to pay $68 billion for Wyeth, and Roche will buy the remaining 44% of Genentech for $46.8 billion (C&EN, March 16, page 5). This is a total of $169.8 billion, and meanwhile the international banking system failed and still has not started lending to ordinary clients! What is going on? This strikes me as an arms race taking place among giant firms while health care costs increase astronomically for everyone else.

Will Merck and others lower their prices? Will they find new, nongeneric drugs to cure existing and drug-resistant diseases at lower costs? Will the merger mania end with one or two enormous pharmaceutical firms having a "corner" on the drug market?

Richard S. Greeley
St. Davids, Pa.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.